Table 1 General characteristics of included studies
From: Meta-analysis of effect of vernakalant on conversion of atrial fibrillation
Study | N | Treatment groups | Subject characteristics | No. with conversion | |||||
|---|---|---|---|---|---|---|---|---|---|
Regimen | n | Goal follow-up time | Atrial fibrillation time | Age (Years) | Men (%) | n/N | % | ||
Camm 2011 | 232 | Vernakalant | 116 | 1 week | AF 3 to 48 | 63 | 63 | 60/116 | 51.7% |
3 mg/kg IVI f/b | hrs | ||||||||
2 mg/kg if | |||||||||
required 15 min | |||||||||
later | 6/116 | 5.2% | |||||||
Amiodarone 5 mg/kg 60-min IVI f/b 50 mg IVI over additional 60 min | 116 | ||||||||
Pratt 2010 | 239 | Vernakalant | 118 | 30 days | AF 3hrs to | 63 | 65 | 47/118 | 40% |
3 mg/kg IVI f/b | 45 days | ||||||||
2 mg/kg if | |||||||||
required 15 min | 4/121 | 3% | |||||||
later | |||||||||
Placebo | 121 | ||||||||
Roy 2004 | 56 | Vernakalant | 18 | 1 week | AF 3 to 72 | 64 | 61 | 2/18 | 11% |
0.5 mg/kg IVI f/b | hrs | ||||||||
1.0 mg/kg if | |||||||||
required 30min | 18 | 11/18 | 61% | ||||||
later | |||||||||
Vernakalant | |||||||||
2.0 mg/kg IVI f/b 3.0 mg/kg if required 30 min later Placebo | 20 | 1/20 | 5% | ||||||
Roy 2008 | 336 | Vernakalant | 221 | 30 days | AF 3 hrs | 62 | 69 | 83/221 | 37.6% |
3 mg/kg IVI f/b | to 45 days | ||||||||
2 mg/kg if | |||||||||
required 15 min | |||||||||
later | 3/115 | 2.6% | |||||||
Placebo | 115 | ||||||||
Stiell 2010 | 290 | Vernakalant | 229 | AF 3 to 48 | 69 | 136/229 | 59.4% | ||
3 mg/kg IVI f/b | hrs | ||||||||
2 mg/kg if | 1 week | 59 | |||||||
required 15 min | |||||||||
later | 61 | 3/61 | 4.9% | ||||||
Placebo | |||||||||